Premium
MnAl Layered Double Hydroxide Nanoparticles as a Dual‐Functional Platform for Magnetic Resonance Imaging and siRNA Delivery
Author(s) -
Zuo Huali,
Chen Weiyu,
Li Bei,
Xu Kewei,
Cooper Helen,
Gu Zi,
Xu Zhi Ping
Publication year - 2017
Publication title -
chemistry – a european journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.687
H-Index - 242
eISSN - 1521-3765
pISSN - 0947-6539
DOI - 10.1002/chem.201702835
Subject(s) - cytotoxicity , magnetic resonance imaging , biocompatibility , drug delivery , cancer cell , hydroxide , nanoparticle , materials science , mri contrast agent , chemistry , cancer research , cancer , nanotechnology , nuclear magnetic resonance , medicine , biochemistry , in vitro , radiology , organic chemistry , physics
Multifunctional nanoparticles for cancer theranosis have been widely explored for effective cancer detection and therapy. In this work, dually functionalised manganese‐based layered double hydroxide nanoparticles (Mn‐LDH) were examined as an effective anticancer drug/gene delivery system and for T 1 ‐weighted magnetic resonance imaging (MRI) in brain cancer theranostics. Such Mn‐LDH have been shown to accommodate dsDNA/siRNAs and efficiently deliver them to Neuro‐2a cells (N2a). Mn‐LDH have also shown high biocompatibility with low cytotoxicity. Importantly, the cell‐death siRNA (CD‐siRNA) delivered with Mn‐LDH more efficiently kills brain cancer cells than the free CD‐siRNA. Moreover, Mn‐LDH can act as excellent contrast agents for MRI, with an r 1 value of 4.47 m m −1 s −1 , which is even higher than that of commercial contrast agents based on Gd complexes ( r 1 =3.4 m m −1 s −1 ). Altogether, the high delivery efficacy and MRI contrast capability make dual‐functional Mn‐LDH potential bimodal agents for simultaneous cancer diagnosis and therapy.